Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15898007 | 0.83 | GAA (0.33) | GAA | |
| SCHEMBL12661104 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL3265209 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL3265337 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL890112 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL13160461 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL18430748 | 0.80 | GAA (0.31) | GAA | |
| SCHEMBL3266622 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL3268560 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL15889421 | 0.79 | GAA (0.36) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018035005-A1 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-9555038-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160257697-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20150335648-A1 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257697-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, TPMT, RPL35 | GAA 1273/4885ALDH1A1 301/4885 |
| US-20150335648-A1 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, HCCS, CYP3A43 | GAA 852/4885ALDH1A1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.